LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating reaffirmed by stock analysts at Piper Jaffray Companies in a report issued on Wednesday, TipRanks reports.
A number of other equities analysts also recently commented on the stock. Stifel Nicolaus reaffirmed a “buy” rating and issued a $100.00 price objective on shares of LivaNova in a report on Friday, April 5th. BTIG Research restated a “hold” rating on shares of LivaNova in a research note on Wednesday. UBS Group lifted their price objective on shares of LivaNova from $100.00 to $105.00 and gave the company a “neutral” rating in a research note on Tuesday, April 2nd. Zacks Investment Research upgraded shares of LivaNova from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Finally, BidaskClub upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research note on Friday. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. LivaNova presently has an average rating of “Buy” and an average target price of $107.20.
LivaNova stock traded down $1.12 during mid-day trading on Wednesday, reaching $78.99. The company’s stock had a trading volume of 443,451 shares, compared to its average volume of 539,646. The company has a market capitalization of $3.90 billion, a price-to-earnings ratio of 24.92, a price-to-earnings-growth ratio of 3.25 and a beta of 0.57. The firm’s 50 day moving average is $73.17. The company has a current ratio of 0.87, a quick ratio of 0.61 and a debt-to-equity ratio of 0.13. LivaNova has a twelve month low of $64.80 and a twelve month high of $131.54.
In other LivaNova news, Director Alfred J. Novak sold 1,300 shares of the business’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $70.63, for a total value of $91,819.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Damien Mcdonald sold 1,000 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $72.60, for a total transaction of $72,600.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,300 shares of company stock worth $387,999. 0.41% of the stock is owned by company insiders.
A number of institutional investors have recently modified their holdings of LIVN. Nisa Investment Advisors LLC raised its holdings in LivaNova by 8.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,900 shares of the company’s stock worth $137,000 after buying an additional 155 shares during the period. Rockefeller Capital Management L.P. lifted its holdings in shares of LivaNova by 9.6% during the first quarter. Rockefeller Capital Management L.P. now owns 1,981 shares of the company’s stock valued at $193,000 after purchasing an additional 174 shares during the last quarter. Strs Ohio lifted its holdings in shares of LivaNova by 1.1% during the first quarter. Strs Ohio now owns 18,700 shares of the company’s stock valued at $1,818,000 after purchasing an additional 200 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in shares of LivaNova by 1.2% during the first quarter. Oregon Public Employees Retirement Fund now owns 19,448 shares of the company’s stock valued at $1,891,000 after purchasing an additional 232 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV purchased a new position in shares of LivaNova during the first quarter valued at approximately $29,000. Hedge funds and other institutional investors own 84.08% of the company’s stock.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Further Reading: What does the Producer Price Index (PPI) tell investors?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.